登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>B7-H2 >B72-H5221

Human B7-H2 / ICOSLG Protein, His Tag

分子别名(Synonym)

ICOSLG,B7-H2,B7H2,B7RP-1,B7RP1,CD275,GL50,ICOS-L,ICOSL,LICOS,ICOS ligand

表达区间及表达系统(Source)

Human B7-H2, His Tag (B72-H5221) is expressed from human 293 cells (HEK293). It contains AA Asp 19 - Ser 258 (Accession # NP_056074).

Predicted N-terminus: Asp 19

Request for sequence

蛋白结构(Molecular Characterization)

B7-H2 Structure

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 27.8 kDa. The protein migrates as 45-67 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

B7-H2 SDS-PAGE

Human B7-H2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

B7-H2 ELISA

Immobilized Human ICOS, Fc Tag (Cat. No. ICS-H5258) at 1 μg/mL (100 μL/well) can bind Human B7-H2, His Tag (Cat. No. B72-H5221) with a linear range of 5-78 ng/mL (QC tested).

Protocol

 
评论(4)
  1. 151XXXXXXX5
  2. 2人赞
  3. 换了很多家的同类型的抗体,没想到就这样的最靠谱,无论是发货速度、售后服务,还是对产品的定价都无可挑剔,这简直就是广大科研工作者的梦中情人,这么优秀的品牌和试剂值得评价一番,希望品牌越来越好
  4. 2022-4-21
  1. 188XXXXXXX0
  2. 1人赞
  3. 流式一直做不出来,也不知道什么原因,用了这个试剂后没想到证明了我的抗体是有问题的,虽然实验失败了,但是知道了原因也是进步,幸好有这个试剂,要不然真是一错再错了
  4. 2022-4-22
  1. 131XXXXXXX6
  2. 1人赞
  3. 开展新项目,换了很多家的同类型的抗原,达不到预期的试验效果。买了你们公司的抗原后,很快就得到了想要的结果,试验快速,高效的出了结果。
  4. 2022-4-21
 
ACRO质量管理体系
 
 

背景(Background)

ICOS ligand (ICOSLG) is also known as B7 homolog 2 (B7-H2), B7-related protein 1 (B7RP-1) and CD antigen CD275, which belongs to the immunoglobulin superfamily and BTN/MOG family. ICOSLG contains one Ig-like C2-type (immunoglobulin-like) domain and one Ig-like V-type (immunoglobulin-like) domain. Isoform 1 is widely expressed, while isoform 2 is detected only in lymph nodes, leukocytes and spleen. B7-H2 is ligand for the T-cell-specific cell surface receptor ICOS. B7-H2 acts as a costimulatory signal for T-cell proliferation and cytokine secretion and induces also B-cell proliferation and differentiation into plasma cells. B7-H2 could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function.

 

前沿进展

Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside
Luo, Yuan, Liu et al
Trends Cancer (2025)
Abstract: The B7-H family of immune checkpoint molecules is a crucial component of the immune regulatory network for tumors, offering new opportunities to modulate the tumor microenvironment (TME). The B7-H family - which includes B7-H2 (inducible T cell costimulatory ligand, ICOSL), B7-H3, B7-H4, B7-H5 (V-domain immunoglobulin suppressor of T cell activation, VISTA), B7-H6, and B7-H7 (HHLA2) - is known for its diverse roles in regulating innate and adaptive immunity. These molecules can exhibit co-stimulatory or co-inhibitory effects on T cells, influencing processes such as T cell activation, differentiation, and effector functions, and they are involved in the recruitment and polarization of various immune cells. This review explores the structural characteristics, receptor-ligand interactions, and signaling pathways associated with each B7-H family member. We also discuss the family's impact on tumor immunity and potential therapeutic strategies.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Immune marker expression and prognosis of early breast cancer expressing HER3
Lee, Ryu, Nikas et al
Eur J Cancer (2024) 213, 115081
Abstract: There is a strong rationale for targeting HER3, as HER3 contributes to tumorigenesis and treatment resistance. However, the prognostic role of HER3 and their association with immunoregulatory protein expression has not been established.The main objective of this study was to investigate the prognostic role of HER3 expression and identify immunoregulatory marker expression according to HER3 status. HER3 expression and 10 immunoregulatory protein (PD-1/PD-L1/PD-L2/IDO/TIM-3/OX40/OX40L/B7-H2/B7-H3/B7-H4) expression was identified in 320 stage I-III breast cancer patients who received curative surgery at Seoul National University Hospital in 2008. The median follow-up duration was 88.8 months. Criteria for HER3 IHC was adopted from HER2 IHC score and only those with 3 + was considered positive.Among 320 patients, 213 (67.2 %) had luminal A disease, 30 (9.5 %) had luminal B disease, 28 (8.8 %) had HER2-positive disease, and 46 (14.5 %) had triple negative disease. HER3 expression was shown in 153 patients (47.8 %). Tumors with HER3-expression had more immunogenic tumor microenvironment compared to HER3-negative tumor. In addition, patients with HER3 expression had favorable 5-year relapse free survival compared to HER3-negative patients (5-year RFS 92.5 % vs. 85.2 %, p = 0.038). However, in the multivariate analysis, HER3 expression was not a prognostic factor, but expression of immunoregulatory protein was a prognostic factor.This study identified immunoregulatory protein expression according to HER3 status in breast cancer patients. As tumor with HER3 expression have more immunogenic microenvironment, investigating combination treatment of HER3 targeting agent and immunotherapy in HER3 expressing breast cancer may be promising.Copyright © 2024. Published by Elsevier Ltd.
Chemotherapy resistance in acute myeloid leukemia is associated with decreased anti-tumor immune response through MHC molecule and B7 family members
Ge, Yin, Sun et al
Discov Oncol (2024) 15 (1), 221
Abstract: Acute myeloid leukemia (AML) remains challenging due to chemotherapeutic drug-resistance (CDR). Aberrant expression B7 family proteins are involved in tumors evasion. We wonder whether B7 family protein alteration in AML CDR further supports tumor escape. Here, we establish AML cytarabine-resistant cell line U937/Ara-C and report on the expression MHC molecule and B7 family member. HLA-ABC was highly expressed similarly on both cell lines. MIC (MHC class I chain related) A/B and B7-H6 was moderately expressed on the surface of U937 and decreased dramatically by U937/Ara-C. In contrast, enhanced expression of B7-H1 and B7-H7 by U937/Ara-C was observed. HLA-DR and other B7 family members including CD80, CD86, B7-DC, B7-H2, B7-H3, B7-H4, and B7-H5 were not detected by both cell lines. Compared co-cultured with U937, peripheral blood mononuclear cells showed a decreased cytotoxicity when incubated with U937/Ara-C, as indicated by decreased levels of granzyme B and perforin production, accompanied with less TNF-α and lactate dehydrogenase secretion. In conclusion, AML CDR further evades the anti-tumor immune response which may through MHC molecule and B7 family members.© 2024. The Author(s).
Lipid droplets-related Perilipin-3: potential immune checkpoint and oncogene in oral squamous cell carcinoma
He, Liu, Dong et al
Cancer Immunol Immunother (2024) 73 (5), 78
Abstract: Lipid droplets (LDs) as major lipid storage organelles are recently reported to be innate immune hubs. Perilipin-3 (PLIN3) is indispensable for the formation and accumulation of LDs. Since cancer patients show dysregulated lipid metabolism, we aimed to elaborate the role of LDs-related PLIN3 in oral squamous cell carcinoma (OSCC).PLIN3 expression patterns (n = 87), its immune-related landscape (n = 74) and association with B7-H2 (n = 51) were assessed by immunohistochemistry and flow cytometry. Real-time PCR, Western blot, Oil Red O assay, immunofluorescence, migration assay, spheroid-forming assay and flow cytometry were performed for function analysis.Spotted LDs-like PLIN3 staining was dominantly enriched in tumor cells than other cell types. PLIN3high tumor showed high proliferation index with metastasis potential, accompanied with less CD3+CD8+ T cells in peripheral blood and in situ tissue, conferring immunosuppressive microenvironment and shorter postoperative survival. Consistently, PLIN3 knockdown in tumor cells not only reduced LD deposits and tumor migration, but benefited for CD8+ T cells activation in co-culture system with decreased B7-H2. An OSCC subpopulation harbored PLIN3highB7-H2high tumor showed more T cells exhaustion, rendering higher risk of cancer-related death (95% CI 1.285-6.851).LDs marker PLIN3 may be a novel immunotherapeutic target in OSCC.© 2024. The Author(s).
Showing 1-4 of 77 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
B7-H2靶点信息
英文全称:ICOS ligand
中文全称:ICOS配体
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:1详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定